ISMP's second QuarterWatch report shows sharp increase in reports of serious adverse drug events.
This newsletter highlights learnings from ISMP's QuarterWatch report, a pilot program used to identify new drug risks and medication errors reported to the US Food and Drug Administration (FDA).